Advertisement
Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor
Yet 21.4% of tested individuals had Lp(a) elevation
While results were negative for metformin, lifestyle counseling showed surprising promise
Launch of the tool promises to reshape quality assessment across the specialty
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
AHA scientific statement outlines models for high-intensity staffing, specialized expertise and more
5% of flagged ECGs in real-world study were from patients with previously undiagnosed HCM
Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose
Phase 2b trial of aldosterone synthase inhibitor also finds no benefit from dose escalation
Patient series and bench validation support efficacy and safety of CLEVE procedure
Resection, radiotherapy or ablation?
Advertisement
Advertisement